You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A nanotechnology approach to higher brain penetrance and sustained brain delivery of intranasal oxytocin
SBC: DD Therapeutics, LLC Topic: NIDAPsychostimulant abuse is a significant public health problemwithmillion Americans reporting cocaine use andmillion reporting methamphetamine useCurrentlythere are no FDA approved pharmacotherapies to treat stimulant dependencePrevious cocaine medications development efforts have focused on small molecule drugs as they can readily enter the brainThe lack of brain penetrance by large molecules was s ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: 300DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery
SBC: DISCOVERYBIOMED, INC. Topic: NIDCDPrincipal Investigators for Small BusinessDiscoveryBioMedIncDBMand Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global public health challengesfood insecuritypoor nutritional healthand poor compliance with medication useparticularly among children and the elderlySugar and saltthe mainstays to address these challengesfur ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Commercialization of a Rapid Blood Test for Traumatic Brain Injury
SBC: Fawkes Biotechnology, LLC Topic: 100Traumatic brain injuryTBIis a substantial health care issue affecting both civilian and military populationsAlthough extremes of head injury are recognizablemild to moderate TBImmTBIis more difficult to diagnose leading to a need for the identification of circulating biomarkers of brain injury that may facilitate early identificationUsing a rat model of TBI we identified a novel marker of neuronal ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Compact Navigation System for CT-guided Needle Interventions
SBC: 3T Technologies, LLC Topic: NCISummaryThe goal of this proposal is to develop and validate a cost effectiveeasy to use and fully integrated navigation system for needle placement during CT image guided cancer diagnosis and treatmentBackgroundAccurate diagnostic and therapeutic interventions depend on accurate needle insertionwhich is subject to the physicianandapos s visuospatial ability and experienceand could be difficult in ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: NIAAAAbstract Chronic liver injury due to alcohol, metabolic dysfunction, viral hepatitis, or autoimmune disease results in liver inflammation and fibrosis. Liver fibrosis will progress to cirrhosis which is estimated to affect 1–2% of the world’s population. The major clinical consequences of cirrhosis are liver failure and hepatocellular carcinoma (HCC), both of which increase the risk of death. ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
SBC: FasCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of An Integrated High Throughput Imaging and Image Analysis Platform for Muscle
SBC: CytoInformatics LLC Topic: NIADESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL)
SBC: HEALTHCHART LLC Topic: 102Project Summary Abstract Peripheral T cell lymphomaPTCLis a heterogeneous cancer that constitutes up toof all non Hodgkin lymphomaNHLThe World Health Organization classification recognizes a number of distinct subtypes of PTCL but the diagnosis of these different subtypes is challenging even for expert hematopathologistsFurthermoreof PTCL cases are not classifiable into any specific subtype at all ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a protein drug for pancreatic cancer treatment
SBC: ProDa BioTech L.L.C. Topic: NCIAbstract Pancreatic cancers are devastating diseases with five year survival rate less thanCurrentlythere is no effective treatment for advanced diseaseOne major barrier to efficacy of anti tumor therapeutics is the dense desmoplastic stromal responseEvidence suggests that cancer associated pancreatic stellate cellsCAPaSCproduce the stromal collagenThe ECM laid down by CAPaSC is considered to be o ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health